Timber Pharmaceuticals, Inc. (NYSE American: TMBR), the stock was up 20.57% to $1.06in the extended-hours session. The Company focuses on the development and commercialization of treatments for rare and orphan dermatologic diseases. Years of clinical experience and well-established CMC and safety profiles have resulted in the Company’s investigational therapies possessing proven mechanisms-of-action.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
So, What’s the update…
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
January 12, 2021, it was announced that-003, the Timber Pharmaceuticals (TMBR), locally delivered formulation of sitaxsentan for systemic sclerosis treatment, received orphan drug designation from the Food and Drug Administration (FDA).
Read More
Orphan drugs are specially designated to treat, prevent, or diagnose diseases and conditions that affect fewer than 200,000 Americans. Systemic sclerosis is one of the rarest types of autoimmune connective tissue disorders. It causes inflammation and thickening of the skin and other connective tissues due to excess collagen deposition. Those with systemic sclerosis develop abnormalities of the skin, the joints, and the internal organs.
The drug sitaxsentan is a highly selective endothelin (ET-A) receptor antagonist, originally developed as an oral treatment for pulmonary arterial hypertension (PAH). A locally delivered form of sitaxsentan TMB-003, which can reduce collagen and address safety concerns associated with orally administered sitaxsentan, has been developed. TMB-003 is being evaluated by Timber to treat scleroderma and is slated to be submitted to the FDA for approval in 2022 as an Investigational New Drug (IND).
Summary
Analysts have hailed the current Era as prime time for Biotech stock. Technologies of today have enabled new treatments and preventions of diseases previously unimaginable.
Investors will take advantage of substantial long-term profits in the biotech industry during this golden age.